Comparative Oncogenomics Identifies Tyrosine Kinase FES As a Tumor Suppressor in Melanoma
RESEARCH ARTICLE The Journal of Clinical Investigation Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma Michael Olvedy,1,2 Julie C. Tisserand,3 Flavie Luciani,1,2 Bram Boeckx,4,5 Jasper Wouters,6,7 Sophie Lopez,3 Florian Rambow,1,2 Sara Aibar,6,7 Bernard Thienpont,4,5 Jasmine Barra,1,2 Corinna Köhler,1,2 Enrico Radaelli,8 Sophie Tartare-Deckert,9 Stein Aerts,6,7 Patrice Dubreuil,3 Joost J. van den Oord,10 Diether Lambrechts,4,5 Paulo De Sepulveda,3 and Jean-Christophe Marine1,2 1Laboratory for Molecular Cancer Biology, Center for Cancer Biology, Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium. 2Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, Leuven, Belgium. 3INSERM, Aix Marseille University, CNRS, Institut Paoli-Calmettes, CRCM, Equipe Labellisée Ligue Contre le Cancer, Marseille, France. 4Laboratory for Translational Genetics, Center for Cancer Biology, VIB, Leuven, Belgium. 5Laboratory for Translational Genetics, and 6Laboratory of Computational Biology, Department of Human Genetics, KU Leuven, Leuven, Belgium. 7Laboratory of Computational Biology, and 8Mouse Histopathology Core Facility, VIB Center for Brain & Disease Research, Leuven, Belgium. 9Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM, U1065, Université Côte d’Azur, Nice, France. 10Laboratory of Translational Cell and Tissue Research, Department of Pathology, KU Leuven and UZ Leuven, Leuven, Belgium. Identification and functional validation of oncogenic drivers are essential steps toward
[Show full text]